The analysis describes federal and state regulation as parallel layers of protection rather than competing systems. Federal agencies establish nationwide requirements for areas such as food safety, infectious disease control, environmental health, workplace safety, pharmaceuticals, and medical devices. States, meanwhile, often serve as laboratories for public health policy, creating additional safeguards tailored to local conditions. This structure allows the country to maintain common minimum standards while permitting states to respond more aggressively to emerging threats.

That system depends heavily on administrative agencies, which translate broad congressional statutes into detailed technical rules. Agencies such as the Centers for Disease Control and Prevention, the Food and Drug Administration, the Environmental Protection Agency, and the Occupational Safety and Health Administration employ scientific experts who evaluate evidence, assess risks, consult stakeholders, and issue regulations. The process is designed to convert complex scientific findings into enforceable standards, although it also makes agencies vulnerable to political interference and legal challenges.

According to the Viewpoint, recent Supreme Court decisions have altered the legal environment in which these agencies operate. One major shift concerns the degree of deference courts give to agency interpretations of ambiguous statutes. For decades, the so-called Chevron framework allowed courts, in certain circumstances, to accept a reasonable agency interpretation when Congress had not clearly resolved a technical question. The Court’s rejection of that approach has transferred greater interpretive authority from specialized agencies to the judiciary, potentially making health regulations more difficult to develop and defend.

The authors argue that this change is not merely a technical dispute over administrative law. Public health rules frequently involve highly specialized questions, including acceptable levels of chemical exposure, vaccine safety monitoring, disease transmission, drug manufacturing, and the evaluation of statistical evidence. Federal judges may review these issues, but they generally do not have the same institutional expertise, scientific staff, or continuing responsibility for monitoring a health threat. Removing agency deference could therefore encourage more litigation and produce inconsistent interpretations of national health requirements.

The Viewpoint also highlights rulings that make it easier to challenge federal regulations and that constrain the mechanisms agencies use to enforce them. These decisions may expand the time available for regulated entities to bring lawsuits, increase judicial scrutiny of agency procedures, and limit the ability of agencies to impose penalties or resolve disputes internally. In practice, the authors say, such changes can delay implementation of protections even after agencies have completed scientific assessments and formal rule-making procedures.

Political control is another central concern. Federal health agencies are intended to operate under presidential oversight, but their credibility depends on a degree of professional independence. Scientists and regulators must be able to evaluate evidence, communicate risks, and enforce standards without pressure to produce politically convenient conclusions. The authors warn that when courts narrow agency authority while executive officials gain greater control over personnel and policy, public health decisions may become more vulnerable to short-term political priorities.

The consequences could extend beyond Washington. States often rely on federal rules as a baseline, but they also use their traditional public health powers to enact stronger protections. State authority has historically supported measures such as stricter tobacco controls, additional environmental requirements, expanded disease-reporting systems, and consumer protections that exceed federal minimums. The Viewpoint contends that recent judicial decisions have curtailed some of these state-level tools, making it harder for states to challenge federal decisions or supplement them with more protective policies.

This tension is especially important during national emergencies, when scientific evidence changes rapidly and governments must act before every question has been resolved. A federal agency may issue a temporary rule or emergency measure to reduce exposure to a pathogen, chemical, or unsafe product. If the rule is quickly blocked in court, or if states are prevented from adopting stronger measures, the result may be a regulatory gap during the period when protection is most urgently needed. The authors call for renewed attention to institutional design, scientific expertise, and the constitutional role of states in protecting population health.

The JAMA analysis does not portray federal agencies as immune from error or political accountability. Instead, it argues that oversight should improve agency performance without dismantling the expertise-based system that makes modern public health regulation possible. Gostin and colleagues suggest that Congress, courts, federal officials, and state governments must clarify their respective responsibilities and preserve meaningful avenues for evidence-based action. As legal battles over agency authority continue, the authors warn that the outcome will shape more than bureaucratic procedure: it may determine how quickly and effectively the United States can respond to the next infectious disease outbreak, environmental hazard, unsafe product, or public health emergency.

Subject of Research: Federal and state public health authority, administrative agencies, Supreme Court decisions, and the legal foundations of public health protections.

Web References: https://doi.org/10.1001/jama.2026.15473

References: Gostin LO et al. JAMA. DOI: 10.1001/jama.2026.15473.

Keywords: public health, federal agencies, state health safeguards, Supreme Court, administrative law, health policy, regulatory independence, scientific evidence, government oversight, public health emergencies

Professor Gilmore’s authoritative analysis underscores a fundamental truth: the forces driving environmental degradation and those harming human health are not discrete issues but are integrally linked, upheld by identical corporate behaviors and strategies. Industries such as fossil fuels, ultra-processed foods, alcohol, and tobacco wield considerable influence, systematically employing tactics designed to mislead scientific discourse, capture regulatory bodies, and lobby against effective legislation. These practices perpetuate a cycle wherein corporate profits are prioritized over climate sustainability and population well-being, hindering transformative policies and interventions.

The report dismantles the efficacy of voluntary initiatives and public-private partnerships touted by commercial actors, framing them instead as corporate strategies that deftly mask conflicts of interest and dilute accountability. Professor Gilmore cautions that self-regulation or government collaborations with these industries offer an illusion of progress while often entrenching corporate agendas within public policy frameworks. She draws parallels to the historical trajectory of tobacco control, where robust binding regulations and the protection of policymaking from corporate interference were instrumental in achieving public health victories.

From an economic standpoint, Professor Gilmore challenges the pervasive narrative that regulation imposes undue burdens on economic growth. She elucidates that the true economic calculus must incorporate the extensive costs inflicted by commercially driven climate and health damage—costs that far outweigh those associated with proactive regulatory measures. The report advocates for governments to rescind harmful subsidies, realign fiscal and trade policies with climate and health goals, and insulate policy processes from corporate capture, thereby fostering resilient systems that prioritize societal welfare.

Integral to this discourse is the imperative of governance innovation, where transparency, accountability, and independent monitoring form the pillars of effective public health and environmental policy. Professor Gilmore argues that rebuilding regulatory frameworks—rooted in empirical evidence and free from corporate distortion—is paramount to curbing the influence wielded by multinational corporations across sectors. This reimagined governance architecture, she asserts, will be critical to balancing the power asymmetry between global corporate entities and public authorities.

Professor Gilmore’s contributions to the WHO Pan-European Commission illustrate a rigorous examination of the systemic barriers that commercial determinants pose to health equity and environmental protection. Her work, supported by the WHO Council on the Economics of Health for All, identifies recurring corporate tactics including the manufacture of doubt through skewed scientific research, systematic lobbying to weaken regulatory efforts, and leveraging corporate social responsibility to evade stringent oversight. This engagement provides a comprehensive blueprint for deconstructing corporate interference and enhancing public policy integrity.

The conceptual framework underpinning Professor Gilmore’s advocacy reveals how commercial interests exploit regulatory loopholes and fragment policymaking processes to preserve business as usual. Her insights extend beyond criticism, outlining constructive pathways for governments to enact binding regulations that align economic activities with the urgent imperatives of climate resilience and public health promotion. This paradigm shift is posited as not merely desirable but essential for the sustainability of future generations and planetary ecosystems.

At the heart of these findings lies the pivotal assertion that effective regulation must transcend incrementalism and voluntary compliance. Professor Gilmore emphasizes that enforceable, transparent, and science-driven policies are indispensable to dismantling the entrenched influence of multinational corporations, thereby catalyzing systemic change. This position aligns with a growing global consensus that sustainable development strategies must integrate stringent oversight of commercial determinants to realize equitable health outcomes and safeguard environmental integrity.

Furthermore, Professor Gilmore situates her research within broader multidisciplinary collaborations, including the Local Health Global Profits consortium, which unites leading UK research institutions to interrogate and address commercial determinants at the municipal governance level. This integrative approach highlights the vital role of localized policy interventions in complementing national and international regulations, underscoring the complexity and scale of the challenge.

Expertise in public health policy, environmental governance, and climate action converge in Professor Gilmore’s innovative research agenda, positioning her at the forefront of efforts to reconceptualize the relationship between economic development and planetary health. Her urgent message to European policymakers encapsulates a transformative ethos: that safeguarding health and climate for present and future generations hinges on disentangling policy frameworks from the undue influence of powerful commercial actors.

In sum, Professor Anna Gilmore’s evidence-based advocacy and comprehensive critique presented to the Pan-European Commission on Climate and Health illuminate a critical path forward—one in which governments must adopt rigorous regulatory frameworks to confront and mitigate the pervasive influence of commercial determinants. This public health and environmental imperative demands immediate, integrated policy action to align economic systems with the profound challenges of climate change and human well-being, marking a potentially decisive turning point in Europe’s response to these intertwined crises.

Subject of Research: Commercial determinants of health, climate policy, and public health governance

Article Title: Leading Public Health Expert Calls for Regulatory Revolution to Tackle Climate and Health Crises in Europe

News Publication Date: 17 May 2026

Web References:

• Pan-European Commission on Climate and Health report: https://www.who.int/europe/groups/pan-european-commission-on-climate-and-health
• Local Health Global Profits (LHGP): https://www.phiuk.org/local-health-global-profits

Image Credits: Laurie Lapworth / University of Bath

Keywords: Public policy, Climate policy, Environmental policy, Health care policy, Regulatory affairs, Commercial determinants of health, Public health governance, Sustainability, Tobacco control, Fossil fuel industry, Corporate influence, Climate and health integration